Our Roadmap
Embark on an extraordinary venture with us as we aspire to redefine cancer screening. While our ultimate goal is to become the universal screening test for all cancers, we understand that monumental journeys commence with a single, decisive step. Explore our roadmap below, envisioning the transformative path ahead.
Currently, we are validating a screening model for prostate cancer only.
In the future, our one test will screen for many diseases!
Model Performance
The best way to measure the performance of a disease model is known as the 'Area Under the Curve' of the 'Receiver Operating Characteristic Curve' or AUC for short. This metric goes from 0.5 to 1.0, where:
- AUC = 0.5 is a random test
- AUC = 1.0 is a perfect test
There are diminishing returns, meaning it's easier to get from 0.5 to 0.6 than from 0.8 to 0.9. Here's how tests are rated:
- AUC = Below 0.8 is a bad test
- AUC = Above 0.8 is a good test
- AUC = Above 0.9 is an excellent test
Steps to Finalizing a Disease Model
1. Academic Research
Understand how the literature indicates our test will perform at screening a new disease
2. Analytical Validation
Create a prototype with new urine samples and train a new algorithm for this specific disease
3. Clinical Validation
Conduct a blinded study to confirm the accuracy of the new disease model
3. Models Clinically Validated
Prostate Cancer
Global Cancer Incidence: 7.8%
Our Test: AUC = Work in Progress
PSA Test: AUC = 0.72
2. Models Analytically Validated
Prostate Cancer
Global Cancer Incidence: 7.8%
Our Test: AUC = 0.88
PSA Test: AUC = 0.68
Kidney Cancer
Global Cancer Incidence: 2.4%
Our Test: AUC = 0.94
Competitor Test: None
1. Models Academically Researched
Breast Cancer
Global Cancer Incidence: 12.5%
Indicative Research: AUC = 0.91
Mamogram Test: AUC = 0.78
Lung Cancer
Global Cancer Incidence: 12.2%
Indicative Research: AUC = 0.95
Competitor Test: None
Colorectal Cancer
Global Cancer Incidence: 10.7%
Indicative Research: AUC = 0.89
FIT Test: AUC = 0.92
Stomach Cancer
Global Cancer Incidence: 6.0%
Indicative Research: AUC = 0.95
Competitor Test: None
Liver Cancer
Global Cancer Incidence: 5.0%
Indicative Research: AUC = 0.96
AFP Test: AUC = 0.94
Cervix Uteri Cancer
Global Cancer Incidence: 3.3%
Indicative Research: None
hrHPV Test: AUC = 0.74
Esophageal Cancer
Global Cancer Incidence: 3.3%
Indicative Research: AUC = 0.86
Competitor Test: None
Thyroid Cancer
Global Cancer Incidence: 3.2%
Indicative Research: None
Competitor Test: None
Bladder Cancer
Global Cancer Incidence: 3.2%
Indicative Research: AUC = 0.93
Competitor Test: None
Non-Hodgkin Lymphoma
Global Cancer Incidence: 3.0%
Indicative Research: AUC = 0.82
Competitor Test: None
Pancreatic Cancer
Global Cancer Incidence: 2.7%
Indicative Research: AUC = 0.86
Competitor Test: None
Leukaemia
Global Cancer Incidence: 2.6%
Indicative Research: None
Competitor Test: None
Endometrial Cancer
Global Cancer Incidence: 2.3%
Indicative Research: AUC = 0.81
Competitor Test: None
Lips & Oral Cavity Cancer
Global Cancer Incidence: 2.1%
Indicative Research: None
Competitor Test: None
Melanoma
Global Cancer Incidence: 1.8%
Indicative Research: None
Competitor Test: None
Ovarian Cancer
Global Cancer Incidence: 1.7%
Indicative Research: None
Competitor Test: None
Brain & CNS Cancer
Global Cancer Incidence: 1.7%
Indicative Research: AUC = 0.85
Competitor Test: None
Laryngeal Cancer
Global Cancer Incidence: 1.0%
Indicative Research: None
Competitor Test: None
Multiple Myeloma
Global Cancer Incidence: 1.0%
Indicative Research: None
Competitor Test: None
Nasopharyngeal Cancer
Global Cancer Incidence: 0.7%
Indicative Research: None
Competitor Test: None
Gallbladder Cancer
Global Cancer Incidence: 0.6%
Indicative Research: None
Competitor Test: None
Oropharyngeal Cancer
Global Cancer Incidence: 0.5%
Indicative Research: None
Competitor Test: None
Hypopharyngeal Cancer
Global Cancer Incidence: 0.5%
Indicative Research: None
Competitor Test: None
Hodgkin Lymphoma
Global Cancer Incidence: 0.5%
Indicative Research: None
Competitor Test: None
Testicular Cancer
Global Cancer Incidence: 0.4%
Indicative Research: None
Competitor Test: None
Salivary Gland Cancer
Global Cancer Incidence: 0.3%
Indicative Research: None
Competitor Test: None
Vulvar Cancer
Global Cancer Incidence: 0.4%
Indicative Research: None
Competitor Test: None
Penile Cancer
Global Cancer Incidence: 0.2%
Indicative Research: None
Competitor Test: None
Kaposi Sarcoma
Global Cancer Incidence: 0.2%
Indicative Research: None
Competitor Test: None
Mesothelioma
Global Cancer Incidence: 0.2%
Indicative Research: None
Competitor Test: None
Vaginal Cancer
Global Cancer Incidence: 0.1%
Indicative Research: None
Competitor Test: None